206874-44-4

Basic information

• Product Name: 2-Diazo-1-(3-methyl-4-nitro-phenyl)-ethanone
• Synonyms: 2-Diazo-1-(3-methyl-4-nitro-phenyl)-ethanone
• CAS NO: 206874-44-4
• Molecular Weight: 205.173
• Mol File: 206874-44-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-Diazo-1-(3-methyl-4-nitro-phenyl)-ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Diazo-1-(3-methyl-4-nitro-phenyl)-ethanone(206874-44-4)
• EPA Substance Registry System: 2-Diazo-1-(3-methyl-4-nitro-phenyl)-ethanone(206874-44-4)

Safety Data

• Hazardous Substances Data: 206874-44-4(Hazardous Substances Data)

Upstream product

• 3113-71-1 3-methyl-4-nitrobenzoic acid 
• 186581-53-3 diazomethane 
• 35675-46-8 3-methyl-4-nitro-benzoyl chloride 

Downstream Products

• 143665-37-6 2-(3-methyl-4-nitrophenyl)acetic acid 
• 924309-88-6 tert-butyl (3-methyl-4-nitrophenyl)acetate 
• 317356-57-3 C₂₉H₂₉BrFN₃O₅ 
• 316121-73-0 tert-butyl 4-amino-3-methylphenylacetate 
• 316121-74-1 (4-[N'-(2-methylphenyl)ureido]-3-methylphenyl)acetic acid 
• 316121-86-5 (4-[N'-(2-chlorophenyl)ureido]-3-methylphenyl)acetic acid 
• 316121-87-6 (4-[N'-(2-bromophenyl)ureido]-3-methylphenyl)acetic acid 
• 317356-54-0 tert-butyl 4-[N'-(2-chlorophenyl) ureido]-3-methylphenylacetate 
• 317356-56-2 tert-butyl 4-[N'-(2bromophenyl) ureido]-3-methylphenylacetate 
• 317356-53-9 C₃₀H₃₂FN₃O₅ 
• 317356-55-1 methyl 4-[(2S,4S)-1-[4-[N'-(2-chlorophenyl)ureido]-3-methylphenylacetyl]-4-fluoro-2-pyrrolidinyl]methoxybenzoate 
• 163981-95-1 (3-Methyl-4-nitro-phenyl)-acetyl chloride 
• 143665-51-4 4-{2-[(3,4-Dimethoxy-benzyl)-methyl-amino]-ethyl}-2-methyl-phenylamine 
• 143665-50-3 2-(4-Amino-3-methyl-phenyl)-N-(3,4-dimethoxy-benzyl)-N-methyl-acetamide 

Relevant articles and documents

Dopamine D3/D2 Receptor Antagonist PF-4363467 Attenuates Opioid Drug-Seeking Behavior without Concomitant D2 Side Effects

Dopamine receptor antagonism is a compelling molecular target for the treatment of a range of psychiatric disorders, including substance use disorders. From our corporate compound file, we identified a structurally unique D3 receptor (D3R) antagonist scaffold, 1. Through a hybrid approach, we merged key pharmacophore elements from 1 and D3 agonist 2 to yield the novel D3R/D2R antagonist PF-4363467 (3). Compound 3 was designed to possess CNS drug-like properties as defined by its CNS MPO desirability score (≥4/6). In addition to good physicochemical properties, 3 exhibited low nanomolar affinity for the D3R (D3 Ki = 3.1 nM), good subtype selectivity over D2R (D2 Ki = 692 nM), and high selectivity for D3R versus other biogenic amine receptors. In vivo, 3 dose-dependently attenuated opioid self-administration and opioid drug-seeking behavior in a rat operant reinstatement model using animals trained to self-administer fentanyl. Further, traditional extrapyramidal symptoms (EPS), adverse side effects arising from D2R antagonism, were not observed despite high D2 receptor occupancy (RO) in rodents, suggesting that compound 3 has a unique in vivo profile. Collectively, our data support further investigation of dual D3R and D2R antagonists for the treatment of drug addiction.

Synthesis and Activity against Multidrug Resistance in Chinese Hamster Ovary Cells of New Acridone-4-carboxamides

A number of tricyclic carboxamides have been synthesized and tested to evaluate their ability to reverse multidrug resistance in the CHRC/5 cell line.Among them the acridone derivatives were the most potent.A key feature is the presence of a dimethoxybenzyl or phenethylamine cationic site, separated from the tricyclic lipophilic part by a carbamoylphenyl chain.Optimization led to compounds 2 orders of magnitude more active than the prototype inhibitors verapamil and amiodarone.On the basis of in vitro and in vivo activities, 9,10-dihydro-5-methoxy-9-oxo-N-phenyl>-4-acridinecarboxamide (84) has been selected for further development.